Cogent Biosciences
COGT
134 hedge funds and large institutions have $859M invested in Cogent Biosciences in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 37 reducing their positions, and 21 closing their positions.
4,929% more call options, than puts
Call options by funds: $704K | Put options by funds: $14K
41% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 37
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
0% more funds holding
Funds holding: 134 → 134 (0)
6.66% less ownership
Funds ownership: 113.12% → 106.46% (-6.7%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
22% less capital invested
Capital invested by funds: $1.1B → $859M (-$244M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$18.3M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$13.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$20.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$13.6M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.82M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$5.71M |
COGT Hedge Fund Activity: Q4 2022 in Review
134 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q4 2022, worth a combined $859M — down 22% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new COGT positions and 21 closed out — a net gain of 1 holder — while 52 added to existing stakes and 37 trimmed.
The largest buyer was RA Capital Management, adding an estimated $24.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $20.3M sold.
- 134 institutional investors held Cogent Biosciences (COGT) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $859M of Cogent Biosciences stock for Q4 2022, down 22% quarter-over-quarter.
- 22 funds opened new Cogent Biosciences positions in Q4 2022 and 21 closed out, a net change of +1 holder.
- The largest Cogent Biosciences buyer in Q4 2022 was RA Capital Management, an estimated $24.6M added.
- The largest Cogent Biosciences seller in Q4 2022 was Avidity Partners Management, an estimated $20.3M sold.
Based on aggregated 13F filings for Q4 2022.